Truist Securities analyst Joon Lee reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $120 price target.
Truist Securities Reiterates Buy on Viking Therapeutics, Maintains $120 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.